Analysts rate AbbVie Inc. (ABBV:NYE) with a Buy rating and a $162 target

SVB Leerink targets down the ABBV stock price to $135.

Based on the AbbVie Stock Forecast from 12 analysts, the average analyst ABBV stock price target is USD 162.61 over the next 12 months. AbbVie Inc’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of AbbVie stock forecast is Neutral, which is based on 7 positive signals and 8 negative signals. At the last closing, AbbVie Inc’s stock price was USD 143.33AbbVie Inc’s stock price has changed by -1.27% over the past week, +7.05% over the past month and +31.11% over the last year.

 

About AbbVie Inc. (ABBV:NYE):

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet’s diseases, SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

 

What we like:

High market capitalization:

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns:

ABBV stock price has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns:

ABBV stock price has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis, for investors seeking high income yields.

Positive cash flow:

AbbVie stock forecast shows that the company had positive total cash flow in the most recent four quarters.

Positive free cash flow:

AbbVie stock forecast shows that the company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth:

ABBV stock price has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth:

ABBV stock price has shown top quartile dividend growth in the previous 5 years compared to its sector.

 

What we don’t like:

High volatility:

AbbVie stock forecast shows that the total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings:

ABBV stock price is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value:

ABBV stock price is trading high compared to its peers median on a price to book value basis.

Poor return on equity:

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor return on assets:

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged:

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the stock analysis and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis:

ABBV stock price is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth:

ABBV stock price has shown below median earnings growth in the previous 5 years compared to its sector.